Stockscreener 앱 받기
1.02
0.97%
-0.01
전일 마감가:
$1.03
열려 있는:
$1.03
하루 거래량:
152.09K
Relative Volume:
0.47
시가총액:
$37.38M
수익:
-
순이익/손실:
$-9.16M
주가수익비율:
-1.7895
EPS:
-0.57
순현금흐름:
$-8.75M
1주 성능:
-8.93%
1개월 성능:
+21.04%
6개월 성능:
-21.54%
1년 성능:
-27.66%
1일 변동 폭
$0.99
$1.04
1주일 범위
$0.9801
$1.10
52주 변동 폭
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
RNXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.02 | 37.75M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
Jobs Data: Is RenovoRx Inc stock a value trapTrade Volume Summary & Real-Time Volume Triggers - baoquankhu1.vn
Gap Down: Will RenovoRx Inc benefit from rate cuts2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Bear Alert: What is RenovoRx Incs book value per share2025 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Pullback Watch: Will RenovoRx Inc outperform its industry peersJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 - Investing News Network
RenovoRx CEO to Provide Update on Targeted Oncology Therapies at AlphaNorth Capital Event - Quiver Quantitative
Market Fear: Can RenovoRx Inc expand its profit marginsWeekly Market Outlook & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Setups: Should value investors consider RenovoRx IncJuly 2025 Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - MSN
How RenovoRx Inc. stock reacts to inflationary pressuresEarnings Miss & Reliable Intraday Trade Plans - Улправда
Will RenovoRx Inc. stock deliver better than expected guidanceJuly 2025 Setups & Long-Term Capital Growth Strategies - ulpravda.ru
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Sahm
Will RenovoRx Inc. stock reach all time highs in 20252025 Market Outlook & Low Risk High Win Rate Picks - Улправда
Is RenovoRx Inc. stock resilient to inflationJuly 2025 Momentum & Capital Protection Trade Alerts - Улправда
How sustainable is RenovoRx Inc. stock dividend payout2025 Risk Factors & Weekly High Potential Stock Alerts - Улправда
Investor Mood: Will RenovoRx Inc stock see PE expansionMarket Sentiment Report & Real-Time Buy Zone Alerts - moha.gov.vn
Can RenovoRx Inc. stock continue upward trendTrade Risk Assessment & Growth Focused Stock Pick Reports - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - GlobeNewswire
Will RenovoRx Inc. stock see PE expansionShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Investing News Network
New study aims to make pancreatic cancer chemo hit tumors, not the whole body - Stock Titan
RenovoRx (NASDAQ:RNXT) Stock Price Down 1% – Here’s Why - Defense World
Will RenovoRx Inc. stock pay special dividends2026 world cup usa national team quarterfinals defensive leaders high defensive line knockout prediction expert opinion - ulpravda.ru
RenovoRx receives Nasdaq notice for bid price noncompliance - MSN
RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance - TipRanks
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Aug Opening: How RenovoRx Inc stock responds to policy changesQuarterly Profit Summary & Smart Swing Trading Techniques - Bộ Nội Vụ
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 By Investing.com - Investing.com Australia
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com India
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength - Nasdaq
Is RenovoRx Inc. stock attractive for growth ETFsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers - Smartkarma
How RenovoRx Inc. stock performs during Fed tightening cyclesIndex Update & Safe Capital Growth Stock Tips - Улправда
How RenovoRx Inc. stock responds to policy changesJuly 2025 Retail & Capital Efficient Trade Techniques - DonanımHaber
CEO Bagai Buys 5,000 ($4.3K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
Why RenovoRx Inc. stock could outperform in 2025Trade Risk Report & Short-Term High Return Strategies - DonanımHaber
RenovoRx Earnings Notes - Trefis
RenovoRx Executive Makes a Significant Stock Purchase! - TipRanks
Chmn Agah Buys 12,000 ($10.2K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
RenovoRx CMO Ramtin Agah Buys 12,000 Shares - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) CMO-director purchases 12,000 shares at $0.85 - Stock Titan
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - Investing News Network
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO GI 2026 on Innovative Targeted Therapy for Pancreatic Cancer - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 - Stock Titan
Transcript : RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, Dec-09-2025 through Dec-10-2025 - marketscreener.com
RNXT: Six-month survival benefit and strong early revenue position the company for growth in 2026 - TradingView — Track All Markets
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Investing News Network
Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx (RNXT) Stock Analysis Report | Financials & Insights - Benzinga
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Renovorx Inc 주식 (RNXT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
| Agah Ramtin | Chief Medical Officer |
Jun 05 '25 |
Buy |
1.40 |
21,000 |
29,400 |
734,460 |
4.73%
0.92%
자본화:
|
볼륨(24시간):